Abstract: The present invention relates to a water-based cosmetic wherein a hydrophobic powder is directly dispersed in the water phase of the water-based cosmetic, the water-based cosmetic having the excellent smoothness, water resistance and cosmetic durability characteristic of hydrophobic powders, while maintaining the refreshing sensation of use that is inherent in water-based cosmetics. The invented water-based cosmetic is characterized by comprising: (A) 0.1 to 5 mass % of a polyether-modified silicone having an HLB (Si) of 5 to 14; (B) one or more hydrophilic thickeners; (C) a polyol and/or an ethyl alcohol; and (D) one or more hydrophobic powders chosen from among metal oxides hydrophobically treated without using a metal soap, hydrophobic organic powders and silicone powders; wherein the (D) hydrophobic powder is dispersed in the water phase.

Abstract: A tattoo-enhancing wipe provides a wipe impregnated with two enhancing oils. The oils may be compounded with an emulsifier and water for improved dispersion and absorption.

Abstract: The present specification discloses a composition comprising an umbel (masterwort, Peucedanum ostruthium) extract as an active ingredient. The composition disclosed in the present specification exhibits the effect of reducing melanogenesis or inhibiting tyrosinase activity by comprising the umbel (masterwort, Peucedanum ostruthium) extract. As a result of the effect, the umbel (masterwort, Peucedanum ostruthium) extract of the present specification can exhibit a whitening effect and thus can be widely used as a whitening composition in the field of pharmaceuticals or cosmetics.

Abstract: A topical composition for anti-aging and anti-UV damage treatment of the skin includes water soluble extract of Uncaria species, Arabidopsis thaliana extract, alpha lipoic acid, dimethylethanolamine, tetrahexyldecyl ascorbate, dimethyl sulfoxide, Glycyrrhiza Glabra (licorice) root extract, methylsulfonylmethane, phytosterols, D-ribose, tocotrienol, tocopherol, glucosamine hydrochloride, Pisum sativum extract; silicates of sodium, magnesium and aluminum, and a dermatologically acceptable liposomal delivery medium. The composition is useful in a method using it for anti-aging skin treatment effecting DNA repair in both the nucleus and the mitochondria. The topical composition can be applied on the skin of a person daily, and can also be applied in a dermal infusion treatment, with or without micro-dermal abrasion or skin suction.

Abstract: A skincare stimulant having an effective dose of platelets and pharmaceutically acceptable solvents and/or excipients, where the effective dose refers to the presence of at least 1000 platelets in every milliliter of skincare stimulant. A method for treating a skin condition selected wrinkles, amyloidosis and keratosis pilaris includes spraying or spreading the skincare stimulant having over a body area, where the skincare stimulant is a solution having a concentration of 1000-10000 platelets per milliliter of the solution, wherein a source of the platelets is a platelet dry powder having less than 30% of plasma protein, based on the weight of the platelet dry powder.

Abstract: The present invention provides a topical gel cream composition containing oil soluble UV filters.

Abstract: A dissolvable film for delivering a pharmaceutical agent comprises a first water soluble polymer in an amount of from 2 to 35 weight percent and having a molecular weight from about 5,000 daltons to about 49,000 daltons; a second water soluble polymer in an amount of from 2 to 35 weight percent and having a molecular weight greater than 60,000 daltons; and a pharmaceutically active ingredient. The film has a thickness of about 20 microns to about 1200 microns and is configured to disintegrate after contact with a mucous membrane and thereby release the active ingredient.

Abstract: The present invention relates to effervescent compositions which are resistant to water vapour in the atmosphere and to methods of preparing such compositions. In particular, the invention relates to an effervescent composition comprising a co-crystal. The co-crystal comprises an acidic component and a basic component is separate. The co-crystal comprising the acidic component is resistant to water uptake avoiding initiating the effervescence prematurely. Upon dissolution of the co-crystal and the basic component effervescence occurs.

Abstract: The invention generally relates to compositions and methods for treating cancer. In certain embodiments, the invention provides methods that involve treating a cancer in a patient in which cancerous cells overexpress epidermal growth factor receptor as compared to non-cancerous cells. The methods involve administering a first composition including anthrax protective antigen modified to bind an epidermal growth factor receptor of a cell, and administering a second composition including anthrax lethal factor N-terminus fused to a catalytic domain of Diphtheria Toxin A. Binding of anthrax lethal factor N-terminus to anthrax protective antigen results in internalization of Diphtheria Toxin A into the cancerous cell, which triggers apoptosis by inactivation of critical elongation factors.

Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.

Abstract: The invention relates to fat emulsions, particularly to a use of high-concentration glycerol in freeze-thaw resistant emulsions and a free-thaw resistant emulsion thereof. The said high-concentration glycerol is the glycerol that is greater than or equal to 3 w/v % in the emulsion composition. The maximum percentage of the glycerol in the emulsion is 50 w/v %. When the percentage of the oil in the emulsion is 2%-30 w/v %, the glycerol is more than or equal to ? of the oil in the emulsion. The invention comprises a drug-contained emulsion through including drugs. Compared with prior arts, the invention provides a freeze-thaw resistant emulsion which tolerates the low-temperature freeze-thaw experiments, avoiding the pharmaceutical stability issues due to the temperature changes during the emulsion transport, storage and utilization, ensuring medicine quality, meanwhile it drastically reduces the requirements of the transport and storage conditions as well as the medicine costs.

Abstract: The present invention relates to a rhinovaccination system of influenza vaccine, comprising a medical syringe filled with an influenza vaccine composition which comprises an inactivated whole influenza virion and a gel base material comprising carboxy vinyl polymer to administer the influenza vaccine composition to nasal mucosa, which is characterized by not comprising an adjuvant.

Abstract: The present invention has a purpose to achieve desired spray characteristics when a pharmaceutical formulation is sprayed by means of a rhinal spray nozzle used for a metered-dose syringe-based squirt. The present invention relates to a rhinal spray nozzle used for a medical syringe having a tip opening in fluid communication with a syringe barrel for storing a pharmaceutical formulation. The rhinal spray nozzle comprises a hollow nozzle body having a tip portion defining a nozzle orifice thereon, a solid packing rod arranged within the nozzle body, and a nozzle chamber defined between the packing rod and the nozzle body to allow a fluid communication between the tip opening and the nozzle orifice, wherein the formulation comprises the gel material containing viscosity modification agent and carboxy vinyl polymer of which viscosity is modified by applying an exogenous shear force, and wherein the nozzle orifice has a diameter in a range between 0.25 mm and 0.30 mm.

Abstract: A method of reducing a friction coefficient of a surface is disclosed herein, comprising attaching a water-soluble polymer to the surface, and contacting the water-soluble polymer with liposomes, thereby coating the surface with an amphiphilic lipid. Further disclosed herein are solutions comprising a water-soluble polymer attachable to the surface, liposomes, and an aqueous carrier, for reducing a friction coefficient of a surface, and methods utilizing same. Articles of manufacture comprising a substrate coated by a water-soluble polymer which is coated by an amphiphilic lipid are also described, as are uses and methods for treating a synovial joint disorder associated with increased articular friction.

Abstract: The present invention provides liposomes loaded with chelating agents, pharmaceutical formulations including these liposomes and methods of making chelating agent liposomes. Because the chelating agents are loaded in the liposome with high efficiencies, the liposomes are of use in treatment of metal ion overload in subjects. The liposomes can include two or more different chelating agents of different structures and affinities for metal ions.

Abstract: There are provided liposomes, comprising cationic lipids, a membrane stabilizing lipid and at least one lipid conjugated to a polyethylene glycol (PEG) derivative, in particular PEG-amine, the liposomes are coated with a glycosaminoglycan, in particular, Hyaluronic Acid (HA), compositions comprising the same, methods for their preparation and uses thereof for the efficient delivery of nucleic acids, such as, si RNA molecules and for treating various conditions, such as cancer.

Abstract: The invention relates to a novel free-flowing powder pharmaceutical formulation for the delivery of a poorly-water-soluble drug substance that increases the solubility and bioavailability of the poorly-water soluble drug substance, as well as to a method of making the free-flowing powder pharmaceutical formulation. The invention also relates to dispersed particles that disperse instantaneously from the free-flowing powder formulation when the formulation is added to water, aqueous solvent, or organic solvent, wherein the bulk distribution of the poorly-water soluble drug substance of the free-flowing powder formulation in the dispersed particles is uniform. Such dispersed particles increase the bioavailable surface area of the poorly water-soluble drug substance and facilitate the drug substance's dissolution.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: A process and system for recovering gel-mass from a gel-mass-containing waste material. The process comprises retrieving the gel-mass-containing waste material from an encapsulation process; melting the retrieved waste material to provide an oil phase and a non-oil phase; retrieving the non-oil phase to produce a recovered gel-mass; and recycling the recovered gel-mass for combination with fresh encapsulating material to provide a combined encapsulating material for use in encapsulating a same lot of the same product which was being encapsulated in the step that produced the gel-mass-containing waste material from which the gel-mass was obtained. The system comprises a heated accumulator for receiving and melting the gel-mass-containing waste material to provide an oil phase and a non-oil phase; a pumping system; an optional mixer; and a control system.

Abstract: The present invention provides carbonate apatites with a suitable particle size (average particle size and maximum particle size) as well as small variance (?2) of particle sizes. Provided is a method of manufacturing a carbonate apatite, the method comprising the step of incubating a mixture comprising a calcium ion, a phosphate ion, and a hydrocarbon ion, wherein an incubation temperature is 10° C. or lower and an incubation time of 10 minutes or less. Further, a carbonate apatite made by this method (e.g., carbonate apatite with a maximum particle size of 700 nm, average particle size of 30 nm and drug encapsulation rate of 98%, all in nanometer size) is provided.

Abstract: Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.

Abstract: The present invention relates to modified release compositions comprising multitude of modified release beads. The modified release beads comprise a matrix of at least one active ingredient, at least one ion exchange resin, at least one non polymeric multifunctional excipient; substantially coated with at least one outer release rate modifying layer.

Abstract: Described herein are polymeric nanoparticles that include a therapeutic agent, and methods of making and using such therapeutic nanoparticles. In some embodiments, the contemplated nanoparticles may include an excipient.

Abstract: There is provided a core-shell particle having pores extending through its shell and a plurality of polymers that are bonded to the outer surface of the shell, wherein the polymers are comprised of repeating monomer units of formula (1): [Formula should be inserted here] wherein the substituents are as defined herein. There is also provided a method of synthesizing the core-shell particle and use of the core-shell particle as a delivery agent.

Abstract: Provided herein are p-GlcNAc nanoparticle/nucleic acid compositions. In one aspect, the p-GlcNAc nanoparticle/nucleic acid compositions comprise deacetylated poly-N-acetylglucosamine lactate derivative nanoparticles less than 500 nm and a nucleic acid. Also, provided herein are methods for administering a nucleic acid to a subject, the method comprising administering to the subject a p-GlcNAc nanoparticle/nucleic acid composition. In certain embodiments, the p-GlcNAc nanoparticle/nucleic acid composition is administered subcutaneously to the subject.

Abstract: Polymeric matrices for the controlled release of medicaments for the topical transdermal use comprising copolymers of acrylic and/or methacrylic acid or esters thereof having a Tg lower than 0° C., whose free carboxy groups are salified with compatible organic or inorganic bases. The matrices of the invention allow to prepare therapeutical systems for the controlled-release of active principles through the transdermal route, thus solving stability, solubility and/or bioavailability problems of the active ingredient within the matrix.

Abstract: A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance.

Abstract: The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.

Abstract: The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof.

Abstract: The invention generally relates to methods of using adrenergic receptor agonists for the treatment of skin and mucosal superficial wounds. Some of the preferred adrenergic receptor agonists include epinephrine, phenylephrine, norepinephrine, methoxamine, and mixtures thereof. Methods according to the invention are especially effective to control superficial skin and mucosal bleeding and accelerate healing time.

Abstract: The invention relates to a pharmaceutical patch for transdermal administration of the pharmacologically active ingredient Tapentadol or a physiologically acceptable salt thereof, the patch comprising a surface layer, an adhesive layer which comprises a pressure sensitive adhesive and at least a portion of the total amount of the pharmacologically active ingredient that is contained in the pharmaceutical patch, and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer.

Abstract: The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.

Abstract: There are described compositions comprising chlorhexidine or a salt thereof and at least one peptide, and their use in the treatment of infections caused by bacteria, fungi and/or yeasts, in particular in the veterinary field.

Abstract: The present invention provides a preparation method for agomelatine-resorcinol and agomelatine-hydroquinone co-crystals using the solvent-antisolvent method that enables a commercial mass production. The co-crystals prepared by the preparation method of the present invention displays high dissolution rate and high stability in acidic-to-neutral media.

Abstract: This invention relates to a system comprising a formulation/composition and an applicator wherein the formulation/composition is designed to treat hemorrhoids.

Abstract: Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.

Abstract: A quinonemethide triterpenoid is administered to subjects with multidrug-resistant cancer, in particular a cancer with enhanced expression and/or functional activity of ABC transporter proteins such as P-glycoprotein and/or an apoptosis-deficient, in particular p53-, Bax- or Bak-deficient, cancer, i.e. specific subgroups of subjects with cancer. The quinonemethide triterpenoid is suitable to treat cancer allowing for an accumulation of cytotoxic or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity towards the multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds. Methods for specifically targeting cancer cells with multidrug-resistance and methods for potentiating the activity of a chemotherapeutic compound in those cancer cells are also disclosed. A kit including a quinonemethide triterpenoid and a chemotherapeutic compound is also provided.

Abstract: Disclosed herein are methods for (a) treating, inhibiting, or reducing aging of a subject, (b) treating, inhibiting, or reducing an age-related symptom or an age-related disease in a subject, and/or (c) increasing the lifespan of a subject which comprise administering to the subject one or more ketobutyrate compounds and compositions thereof.

Abstract: The present disclosure relates to compositions and methods for contraception that also enhance the efficacy of microbicides. Such compositions serve the dual purpose of preventing pregnancy and lessening the risk of spreading sexually transmitted diseases. More specifically, the compositions and methods relate to syngergistic contraceptive microbicide and antiviral compositions comprising a combination of a contraceptive microbicide and an antiviral agent in an acidic carrier that enhances the efficacy of both the contraceptive microbicide and antiviral agent.

Abstract: Provided herein is a method of using threonate to alter cellular physiology, such as neuronal physiology. A method of the present disclosure may include providing to a medium comprising a cell, a threonate-containing compound, or a precursor thereof, to increase the concentration of threonate in the medium, where the increased concentration of threonate is sufficient to increase the concentration of magnesium in the cell. Also provided is a method that includes administering a threonate-containing compound, or a precursor thereof, to an individual, to increase synaptic density in the brain and/or to treat a neurological disorder, e.g., cognitive impairment. The threonate-containing compound of the present disclosure does not include magnesium threonate.

Abstract: Gentisic acid sodium salt is shown to be useful as a treatment to improve systemic hemodynamics, hepatic mitochondrial function and lactic acidemia in patients with septic shock.

Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.

Abstract: A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.

Abstract: A beverage or food additive for improving an individual's mental and physiological performance, the dietary composition comprising medium chain triglycerides oil, Ginko Biloba, Panax Ginseng, phosphatidylserine, Bacopa Monnieri, and Polygala Tenuifolia. In addition, the dietary composition may optionally contain docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and/or epigallocatechin gallate (EGCG).